biphenyl-2-ylcarbamic acid 1-(2-((4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl)methylamino)ethyl)piperidin-4-yl ester,
revefenacin,
TD-4208,
Revefenacin,
864750-70-9,
TD-4208,
UNII-G2AE2VE07O,
GSK-1160724,
G2AE2VE07O,
GSK1160724,
[1-[2-[[4-[(4-carbamoylpiperidin-1-yl)methyl]benzoyl]-methylamino]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate,
TD-4208; GSK-1160724;[1-[2-[[4-[(4-carbamoylpiperidin-1-yl)methyl]benzoyl]-methylamino]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate,
Yupelri,
Revefenacin [INN],
Revefenacin [WHO-DD],
Revefenacin (USAN/INN),
Revefenacin [USAN:INN],
SCHEMBL356480,
CHEMBL3833319,
GTPL10129,
BCP15793,
EX-A1722,
TD4208,
CS-7743,
DB11855,
SB17262,
HY-15851,
Revefenacin; TD-4208; GSK-1160724,
D10978,
1-(2-(4-((4-Carbamoylpiperidin-1-yl)methyl)-N-methylbenzamido)ethyl)piperidin-4-yl N-((1,1'-biphenyl)-2-yl)carbamate,
Biphenyl-2-ylcarbamic acid, 1-(2-((4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl)methylamino)ethyl)piperidin-4-yl ester,
Carbamic acid, N-(1,1'-biphenyl)-2-yl-, 1-(2-((4-((4-(aminocarbonyl)-1-piperidinyl)methyl)benzoyl)methylamino)ethyl)-4-piperidinyl ester,
ACN-051241,
CID11753673,
CID 11753673,
A15986,
1-(2-(3-((4-carbamoylpiperidin-1-yl)methyl)-N-methylbenzamido)ethyl)piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate,